

Ref. No: FOI1658
Date: 04/04/2025
Subject: Prostate Cancer Patient and Treatment Data

REQUEST

We apologise but we noticed an error in the table we sent you and this has caused some confusion. Please find the corrected sheet attached.

To clarify we are looking for the following information:

I would like to request data on the treatment of patients with hormone therapies for prostate cancer at your Trust for the period January 1, 2023- December 31, 2024. Specifically, I am seeking the following information:

Request for Information

For each of the following hormone therapies used to treat prostate cancer, please provide the number of patients treated at your Trust between 01 January and 31 December (by years 2023 and 2024). For each therapy, broken down the data into the following categories:

1. Total Number of Patients Treated for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)
2. Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)
3. Number of Patients for Whom Hormone Therapy Was Continued for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)
4. Number of patients for Whom Docetaxel was Initiated for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)

The hormone therapies of interest are:

- a. ADT* alone

- b. Abiraterone (Zytiga) in combination with any ADT
- c. Abiraterone (Zytiga) – no ADT
- d. Enzalutamide (Xtandi) in combination with any ADT
- e. Enzalutamide (Xtandi) – no ADT
- f. Apalutamide (Erleada) in combination with any ADT
- g. Darolutamide (Nubeqa) in combination with any ADT
- h. Darolutamide (Nubeqa) in combination with any ADT with docetaxel
- i. Docetaxel in combination with any ADT

***By ADT we mean any of the following drugs: Goserelin (Zoladex), Leuporelin acetate (Prostap), Triptorelin (Decapeptyl), Buserelin acetate (Suprefact), Degarelix (Firmagon), Relugolix (Orgovyx).**

If any part of this information is not available or cannot be provided, please provide whatever information you are able to. I would appreciate it if you could provide the information in an electronic format, preferably in the *attached spreadsheet format*.

RESPONSE

1. Total Number of Patients Treated for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)

The below numbers have been issued from Pharmacy at St Helens and Whiston sites. None of the patients listed for Southport and Ormskirk sites have been supplied any of these drugs direct from Pharmacy.

The drugs are also used as stock on clinics but Pharmacy don't have the information as to which patients have received stock medication.

- Degarelix – 24 patients
- Triptorelin – 27 patients

2. Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)

Unable to answer question 2 as we do not hold this information.

3. Number of Patients for Whom Hormone Therapy Was Continued for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)

Unable to answer question 3 as we do not hold this information.

4. Number of patients for Whom Docetaxel was Initiated for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)

0